Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy v1.0
Version 1.0 of the Duchenne Muscular Dystrophy Therapeutic Area User Guide (TAUG-DMD) was developed under the CFAST Program and the CDISC Standards Development Process. The TAUG-DMD describes the most common biomedical concepts relevant to Duchenne Muscular Dystrophy, and the necessary metadata to represent such data consistently with Terminology and SDTM.
TA Standards extend the Foundational Standards to represent data that pertain to specific indications within disease areas. CDISC Standards specify how to structure the data; they do not specify what data should be collected or how to conduct clinical trials, assessments or endpoints.
CDISC posts Public Review comments and resolutions to ensure transparency and show implementers how comments were addressed in the standard development process.
TA Specifications show how to modify TAUG examples for various versions of the SDTM and SDTMIG. These specifications assist the FDA and the Japanese PMDA with testing to enable support of the standards and inclusion in their respective Technical Conformance Guides.1,2
The specifications comprise five worksheets in an Excel workbook:
- Read Me – Information on how to read the other worksheets
- Summary – Table of Contents for the TAUG annotated with examples and the domains and variables they use
- Known Issues – A list of modeling issues noted in the TAUG
- Domains – Domains used and their status in different versions of the SDTMIG
- Variables – Variables used and their status in different versions of the SDTM
CDISC Standards facilitated the interoperability of datasets in a data sharing platform to foster the development of a disease progression model for Duchenne Muscular Dystrophy. The Duchenne Parent Project wrote a corresponding blog about the need for CDISC standards in their research